Results 221 to 230 of about 2,138,197 (387)
Five Cases of Non-Hodgkin B-Cell Lymphoma of the Ovary [PDF]
Taylan Şenol +6 more
openalex +1 more source
A Stringent dUPlex‐activated Error Robust (SUPER) DNAzyme system enables real‐time imaging of alternative mRNA splicing (e.g., Bcl‐xL/Bcl‐xS) in living cells via target‐triggered split‐DNAzyme reassembly and dual‐color fluorescence. It also achieves mRNA‐selective knockdown through DNAzyme‐based gene regulation, serving as a versatile tool for splicing
Mengru Lin +6 more
wiley +1 more source
Comparison of Diagnostic Utilities in a Canine Retrobulbar Large B-Cell Lymphoma With Multifocal Involvement. [PDF]
Jung R, Bae H, Cho KW, Jung DI, Yu D.
europepmc +1 more source
Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes [PDF]
Annarita Conconi
openalex +1 more source
Dynamic Decoration of DNA Scaffolds for High‐Resolution Cancer Cell Subtyping
This study presents a dual‐mode imaging platform that utilizes self‐assembly and disassembly of DNA scaffolds for high‐resolution cancer cell detection. The structural rigidity of DNA scaffolds effectively prevents cellular internalization for over 300 min.
Xiaolin Hu +15 more
wiley +1 more source
The Role of microRNAs as Potential Biomarkers in Diffuse Large B-Cell Lymphoma. [PDF]
Panteli E +7 more
europepmc +1 more source
Distribution of T-cell subsets in follicular and diffuse lymphomas of B-cell type.
Nancy L. Harris, A K Bhan
openalex +1 more source
SIRT5 desuccinylates and stabilizes RAC2, activating CSF1R‐dependent signaling to drive monocyte differentiation into M0 macrophages and their polarization toward pro‐inflammatory M1 phenotypes in CTX‐induced premature ovarian insufficiency. Inhibiting the SIRT5‐RAC2 axis attenuates inflammation, reduces granulosa cell apoptosis, and preserves ...
Wenjing TanTai +15 more
wiley +1 more source
Presentation of Cutaneous Large B-Cell Lymphoma, Leg Type. [PDF]
Valenzuela FI, Hohnadel MR.
europepmc +1 more source
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang +7 more
wiley +1 more source

